NCT00913133

Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis

Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 516 (actual)
• Sponsor: Canyon Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this trial is to demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis of thrombosis as an alternative to heparin-based anticoagulation.

Detailed description

Hospitalized patients who require DVT prophylaxis and who are not good candidates for heparin-based anti-coagulation were eligible.

Conditions

• Thrombosis

Interventions

Type	Name	Description
DRUG	Desirudin	Desirudin SC 15mg q12h

Timeline

• Start date: 2010-03-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2009-06-04
• Last updated: 2013-01-10
• Results posted: 2013-01-03

Locations

16 sites across 1 country: United States